comprehensive -WSS

comprehensive

author：fashion 2025-09-06 02:05:52 - browse：938

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Life science postdocs should get big pay hike, NIH panel says

focus

WSS

STAT Virtual Event: JPM Recap, Live!

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Will the market for weight loss drugs really reach $100 billion?

Will the market for weight loss drugs really reach $100 billion?

Pediatric cancer treatments threatened by a new FDA policy

Medicare Advantage coverage denials need scrutiny, senators say

entertainment

comprehensive

hotspot

Peter Hotez and the public health issue of online harassment

Ascension's ugly legal battle over care for poor patients in Texas

How one medical school became remarkably diverse

In shift, Texas to cover initial consult for Afghan baby's gene therapy

How to save PrEP access — and even expand it

Organ aging and disease risk measured by new blood test

Medicare proposal to cover medical devices draws a mixed reaction

Gene therapy denied for Afghan refugee whose father aided U.S.

DIEP, the 'gold standard' of breast reconstruction, is under threat

Fetal surgery at risk from Dobbs and new abortion restrictions

hotspot

J&J to emphasize cancer drugs, stop much of its vaccine research

Despite FDA concern, risk that CAR

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Gene therapy denied for Afghan refugee whose father aided U.S.

Diagnostic tests are hitting their mathematical limits

Wikipedia

focus

focus

focus